BIOXCEL THERAPEUTICS INC (BTAI)

Company Profile

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in developing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 183 full-time employees. The company went IPO on 2018-03-08. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is also being developed for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The firm is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, LLC, the Company is developing BXCL701, an investigational, oral innate immune activator that is being developed as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Company Info

BIOXCEL THERAPEUTICS INC

555 Long Wharf Dr

New Haven CONNECTICUT 06511

P: 12036438060

CEO: Vimal Mehta

Employees: 183

Website: https://www.bioxceltherapeutics.com/